PARIS--(Marketwire - Mar 19, 2012) - Cegedim Strategic Data (CSD), leading provider of healthcare market research, has published the results of its study on the evolution of type 2 Diabetes in France up to 2022.

The study uses CSD's longitudinal patient database (LPD) which collects anonymised clinical data on a daily basis from a constant panel of 1,200 physicians covering 1.3 million patients in France.

With this longitudinal patient data, the official figures from the national health surveillance institute (InVS) and demographic data from the national institute of statistics and economic studies (INSEE), CSD forecasted the future trends in diabetes for the period 2012-2022 in France.

Result highlights

France currently has 2.9 million type 2 diabetes patients. According to CSD, this figure will reach more than 5 million in 2022, reflecting a change in the prevalence rate from 4.6% in 2011 to 7.8% in 2022.

The study shows that the increase in prevalence is influenced by the aging of the population but is also heavily influenced by factors such as obesity and a sedentary lifestyle.

CSD also analysed the form of treatment (OAD[1] only, Insulin only, OAD+insulin), and associated therapeutic strategies (mono/bi/tri therapy and higher) as well as their evolution.

This study will also be available for Germany, Spain, Italy and the UK.

These forecasts are derived from historical trends. The calculations do not include new factors that could arise in the future.

About Cegedim Strategic Data:

CSD is a leading Market Research company dedicated to the healthcare industry and operating worldwide. With over 40 years experience in the Pharmaceutical industry, CSD offers a comprehensive range of market research services and solutions to its customers, which include more than 50 global and 500 local Pharmaceutical companies. CSD integrates primary and secondary analyses with its medical expertise to meet its customer's research needs. To learn more, please visit our website: [ www.cegedimstrategicdata.com ]

About Cegedim:

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,200 people in more than 80 countries and generated revenue of EUR911 million in 2011. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit: [ www.cegedim.com ]

[1] OAD = Oral Anti-diabetic

CSD Diabetes Forecasts France: [ http://hugin.info/141732/R/1594716/502118.pdf ]

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: CEGEDIM STRATEGIC DATA via Thomson Reuters ONE [HUG#1594716]